CPH.CA Profile & Description — Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals is focused on commercializing novel formulations of successful, marketed molecules using advanced drug delivery technologies. Co.'s strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Co.'s first product is a fenofibrate formulation marketed in the U.S. as Lipofen®. Co.'s second product, an extended release tramadol, is marketed in the U.S. as ConZip® and in Canada as Durela®. Co.'s third product, a novel formulation of the acne treatment isotretinoin, has been approved by the FDA.